Claims for Patent: 7,459,604

Summary for Patent: 7,459,604

Title:	Methods for generating resistance against CGMMV in plants
Abstract:	The present invention relates to methods for generating resistance against Cucumber Green Mottle Mosaic Virus (CGMMV) in plants, in particular in plants susceptible to infection by CGMMV, such as Cucurbitaceae species, including melon, cucumber, watermelon and bottlegourd. The methods are based on the use of genetic constructs that induce post-transcriptional gene silencing and/or use a nucleotide sequence that encodes a defective variant of the replicase of CGMMV.
Inventor(s):	Onstenk E. V. Fierens; Bernarda Gerharda Johanna (Veenendaal, NL), De Both; Michiel Theodoor Jan (Wageningen, NL)
Assignee:	Keygene N.V. (Wageningen, NL)
Application Number:	10/467,622
Patent Claims:	1. A method for generating resistance in a plant or in a plant cell against infection with Cucumber Green Mottle Mosaic Virus (CGMMV), comprising generating a transformed plant or plant cell by transforming a plant or plant cell with one or more polynucleotide sequences that upon transcription into RNA generate resistance against infection with CGMMV in said plant and produce a sense and an antisense RNA molecule capable of forming a double stranded RNA region by base-pairing between the regions which are complementary, said polynucleotide sequences comprising a first and a second DNA sequence, wherein: said first DNA sequence comprises a promoter, operably linked to a first DNA region capable of being transcribed into a sense RNA molecule with a nucleotide sequence comprising a sense nucleotide sequence of at least 100 consecutive nucleotides having 100% sequence identity with the replicase encoding nucleotide sequence of the genome of the CGMMV virus capable of infecting the plant or the plant cell; said first DNA sequence optionally further comprises a DNA region involved in transcription termination and polyadenylation functioning in plant cells operably linked to said first DNA region; and said second DNA sequence comprises a second DNA region capable of being transcribed into an antisense RNA molecule with a nucleotide sequence comprising an antisense nucleotide sequence including at least 100 consecutive nucleotides, having 100% sequence identity with the complement of said at least 100 consecutive nucleotides of the sense nucleotide sequence; said second DNA sequence optionally further comprises a promoter operably linked to said second DNA region and optionally a DNA region involved in transcription termination and polyadenylation functioning in plant cells operably linked to said second DNA region, and wherein said replicase encoding nucleotide sequence of the genome of the CGMMV virus is: (A) the nucleotide sequence of SEQ ID NO:1; (B) the nucleotide sequence of SEQ ID NO:5; or (C) the nucleotide sequence of SEQ ID NO:3. 2. The method according to claim 1, wherein the transformed plant is generated by crossing transformed parent plants comprising either the first or the second DNA sequence. 3. The method according to claim 1, wherein the transformed plant is generated by transforming a plant cell with the first and second DNA sequence and regenerating a plant from the transformed plant cell. 4. The method according to claim 1, wherein the first and second DNA sequence are integrated separately in the nuclear genome of the plant cell. 5. The method according to claim 1, wherein the polynucleotide sequence is transcribed into an inverted repeat RNA sequence, optionally linked by a spacer and wherein the spacer is preferably an intron. 6. The method according to claim 1, further comprising at least one step of cultivating the transformed plant cell into a mature plant. 7. The method according to claim 1, further comprising at least one step of sexually or asexually reproducing or multiplying the transformed plant and/or a mature plant obtained from the transformed plant cell. 8. The method according to claim 1, in which the plant is a plant that is susceptible to infection with CGMMV, more preferably a plant belonging to the Cucurbitaceae family, such as melon (Cucumis melo), cucumber (C. sativus), watermelon (Citrullus vulgaris) and bottlegourd (Lagenaria siceraria). 9. A transgenic plant or plant cell, obtainable or obtained by a method according to claim 1, or a descendant of such a plant; wherein the plant, plant cell, or descendant comprises said polynucleotide sequences. 10. The transgenic plant or plant cell or descendent according to claim 9, wherein said plant or plant cell or descendent is resistant against infection with strains of CGMMV prevalent in Europe. 11. The plant according to claim 9, being a plant that is susceptible to infection with CGMMV, more preferably a plant belonging to the Cucurbitaceae family, such as melon (Cucumis melo), cucumber (C. sativus), watermelon (Citrullus vulgaris) and bottlegourd (Lagenaria siceraria). 12. A cultivation material such as seed, tubers, roots, stalks, seedlings of a plant according to claim 9; wherein said cultivation material comprises said polynucleotide sequences. 13. The method according to claim 1, wherein the sense RNA molecule comprises a sense nucleotide sequence of at least 150 consecutive nucleotides having 100% identity with the replicase encoding nucleotide sequence of the CGMMV virus genome. 14. The method according to claim 1, wherein said transformed plant or plant cell is resistant against infection with strains of CGMMV prevalent in Europe. 15. The method according to claim 14, wherein said CGMMV strains prevalent in Europe are strains encountered in the cultivation of cucumbers in greenhouses. 16. The method according to claim 1, wherein the sense RNA molecule comprises a sense nucleotide sequence of at least 200 consecutive nucleotides having 100% identity with the replicase encoding nucleotide sequence of the CGMMV virus genome. 17. The method according to claim 1, wherein the sense RNA molecule with a nucleotide sequence comprises a sense nucleotide sequence of at least 550 consecutive nucleotides having 100% sequence identity with the replicase encoding nucleotide sequence of the CGMMV virus genome.

Details for Patent 7,459,604

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-02-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-02-08
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-02-08